Celularity and Vesalius Sign Exclusive US Peptide Manufacturing Agreement
Celularity and Vesalius signed an exclusive agreement covering peptide manufacturing in the United States.
Related stories
Philex Mining Reports Quarterly Operating Revenue of 2.670 Billion Pesos
M impact | EQUITY | Oct 30, 2026, 12:29 AM UTC
Transportadora de Gas del Sur Reports Quarterly Results
The company reported results for the quarter ended September 30; no financial figures are provided.
M impact | EQUITY | Oct 30, 2026, 12:25 AM UTC
Amazon shares fall as AI spending accelerates cash outflow
Amazon's cloud business is performing well, but AI investment is accelerating cash outflow.
M impact | EQUITY | Oct 30, 2026, 12:24 AM UTC
Bambusa Offers All Shares
Bambusa is offering all of its shares.
M impact | EQUITY | Oct 30, 2026, 12:23 AM UTC
Bambusa Upsizes IPO to 10.6 Million Shares at $16 Per Share
M impact | EQUITY | Oct 30, 2026, 12:23 AM UTC
Kolmar Korea to Hold Q3 Results Call for Analysts on Nov. 6
Kolmar Korea plans to present its third-quarter results on an analyst conference call at 10:30 a.m. on Nov. 6, 2026.
M impact | EQUITY | Oct 30, 2026, 12:21 AM UTC